Digital letters could speed up lifesaving heart failure treatment

NCT ID NCT05890131

Completed Knowledge-focused Sponsor: Morten Schou Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether sending digital letters to heart failure patients could help them start taking SGLT-2 inhibitors, a newer heart failure medication, more quickly. Over 5,900 patients in Denmark were invited via digital letter to see a specialist and check if they were eligible. The goal was to see if this simple digital strategy could speed up treatment and improve outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: digital letter
What this could lead to: If successful, this digital strategy could help more heart failure patients start effective medication faster, potentially improving survival and reducing hospital stays.
What could go wrong: This is a completed implementation study, not a drug trial. The approach may not work in other regions or healthcare systems, and the digital letters alone cannot guarantee better outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE

Contacts and locations

Locations

Amager-Hvidovre-Glostrup Hospital

Hvidovre, 2650, Denmark
Bispebjerg-Frederiksberg Hospital

Copenhagen, 2400, Denmark
Herlev and Gentofte University Hospital

Hellerup, 2900, Denmark
Nordsjællands Hospital

Hillerød, 3400, Denmark
Sjællands Universitetshospital - Roskilde

Roskilde, 4000, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.